Returning guest, Dr. Thomas Jones, Professor of Pediatrics and Adjunct Professor of Medicine at the University of Washington School of Medicine and Director of the Cardiac Catheterization Laboratories at Seattle Children’s Hospital and an investigator on the Medtronic Harmony™ Transcatheter Pulmonary Valve (TPV) pivotal trial discusses the one-year outcomes from the Pivotal Trial and 30-day outcomes from the Continued Access Study at a late-breaking session during SCAI (Society for Cardiovascular Angiography & Interventions) Scientific Sessions. The Harmony TPV is the first minimally invasive therapy created to treat patients with a specific type of congenital heart defect of the right ventricle.
Thomas K. Jones, MD is a Professor of Pediatrics and Adjunct Professor of Medicine at the University of Washington School of Medicine and the Director of the Cardiac Catheterization Laboratories at Seattle Children’s Hospital. Dr. Jones is a graduate of the Jefferson Medical College in Philadelphia. After completing his pediatrics residency at the University of Washington and his pediatric cardiology fellowship training at the University of Colorado and the Denver Children’s Hospital, Dr. Jones returned to Seattle where he spent the first 8 years of his career in private practice. In 1991 Dr. Jones helped create the Children’s Heart Center at the Seattle Children’s Hospital. In the same year he joined the academic faculty of the University of Washington and became the first Director of the Cardiac Catheterization Laboratories at the Seattle Children’s Hospital. Seattle Magazine has repeatedly named him among Seattle’s Top Doctors. Dr. Jones’ lifelong work has focused on congenital and structural interventional cardiac catheterization in children and adults. He has worked to pioneer several less invasive techniques to correct congenital heart conditions. He has authored over 100 manuscripts, book chapters, abstracts and editorials and has participated as an investigator in over 20 multicenter clinical trials in the U.S. Dr. Jones collaborates with emerging technology companies to develop and test new products designed to treat congenital and structural heart conditions. His research interests are currently focused on percutaneous heart valve implantation. He continues to serve on numerous national committees and task forces promoting clinical guidelines and practice standards for patients with congenital heart disease. He is also committed to working with regulatory bodies on novel approval guidelines that will improve patient access to improved cardiovascular devices needed to treat the uncommon conditions that pediatric cardiologists face every day.